[1]雷礼辉,李峰,罗光平,等.椎体CT值对原发性骨质疏松症唑来膦酸钠疗效的评价价值[J].中华老年骨科与康复电子杂志,2022,(05):285-289.[doi:10.3877/cma.j.issn.2096-0263.2022.05.006]
　Lei Lihui,Li Feng,Luo Guangping,et al.Predictive value of changes in CT value of vertebral body for the efficacy of zoledronate sodium in primary osteoporosis[J].Chin J Geriatr Orthop Rehabil(Electronic Edition),2022,(05):285-289.[doi:10.3877/cma.j.issn.2096-0263.2022.05.006]
点击复制

椎体CT值对原发性骨质疏松症唑来膦酸钠疗效的评价价值()
分享到：

中华老年骨科与康复电子杂志[ISSN:1674-3911/CN:11-9292/R]

卷:
期数:
2022年05期
页码:
285-289
栏目:
骨质疏松
出版日期:
2022-10-05

文章信息/Info

Title:
Predictive value of changes in CT value of vertebral body for the efficacy of zoledronate sodium in primary osteoporosis
作者:
雷礼辉1; 李峰3; 罗光平1; 刘洪1; 杨骐彰2; 吴涛1; 翁睿1
418000 怀化市第一人民医院 脊柱外科1；418000 怀化，湖南医药学院影像科2；418000 怀化，湖南医药学院第一附属医院骨科3 通信作者：李峰，Email：lfnagna@163.com
Author(s):
Lei Lihui1;  Li Feng3;  Luo Guangping1;  Liu Hong1;  Yang Qizhang2;  Wu Tao1;  Weng Rui1.
1Department of Spine Surgery, Huaihua First People’s Hospital, Huaihua 418000, China; 2Department of Imaging, Hunan Medical College, Huaihua 418000, China; 3Department of Orthopedics, the First Affiliated Hospital of Hunan Medical College, Huaihua 418000, China
关键词:
原发性骨质疏松症;  椎体CT值;  唑来膦酸钠疗效;  评价价值
Keywords:
Primary osteoporosis;  CT value of vertebral body;  Efficacy of zoledronate sodium;  Predictive value
DOI:
10.3877/cma.j.issn.2096-0263.2022.05.006
文献标志码:
A
摘要:
目的 探讨椎体CT值变化对原发性骨质疏松症（OP）唑来膦酸钠疗效的评价价值。方法 选取2018年5月至2021年4月医院收治的152例原发性OP患者为研究对象，所有患者均采用唑来膦酸钠治疗，统计治疗后12个月疗效。收集患者临床资料，采用Logistic回归分析影响原发性OP患者唑来膦酸钠治疗疗效的因素，用受试者工作特征（ROC）曲线分析影响因素对原发性OP唑来膦酸钠疗效的评价价值。结果 152例原发性OP患者脱落2例，剩余150例患者中59例患者疗效满意，91例患者疗效不佳。将单因素分析有统计学意义的LDLC水平、25-羟维生素D、腰椎体骨松质L1 △CT值为自变量进行Logistic回归分析，结果显示腰椎体骨松质L1 △CT值（OR=4.084，95% CI：1.680，9.925）、25-羟维生素D（OR=3.640，95% CI：1.498，8.847）是影响原发性OP唑来膦酸钠疗效的独立因素（P＜0.05）。ROC曲线显示腰椎体骨松质L1 △CT值评价原发性OP唑来膦酸钠疗效的AUC高于25-羟维生素D（P＜0.05）。结论 原发性OP患者存在唑来膦酸钠治疗疗效不佳风险，椎体CT值变化、25-羟维生素D水平与原发性OP唑来膦酸钠疗效有关，且二者评价原发性OP唑来膦酸钠疗效效能良好。
Abstract:
Objective To explore the predictive value of CT value changes of vertebral body for the efficacy of zoledronate sodium in primary osteoporosis (OP). Methods 152 patients with primary OP who were admitted to the hospital from May 2018 to April 2021 were selected as the research objects. All patients were treated with zoledronic sodium, and the curative effect was calculated 12 months after treatment. Patient clinical data were collected. Logistic regression was used to analyze the factors that affect the efficacy of zoledronate in patients with primary OP. Receiver operating characteristic (ROC) curve was used to analyze the evaluation value of influencing factors on the efficacy of zoledronate in primary OP. Results 2 patients dropped out. Among the remaining 150 patients, 59 patients had satisfactory curative effects, and 91 patients had poor curative effects of the 152 patients with primary OP. Logistic multivariate regression analysis showed that lumbar vertebral body cancellous bone L1 △CT value (OR=4.084, 95% CI: 1.680, 9.925), 25-hydroxyvitamin D (OR=3.640, 95% CI: 1.498, 8.847) were the influencing factors Independent factors for the efficacy of zoledronate sodium in patients with OP. The ROC curve showed that the AUC of lumbar vertebral cancellous bone L1 △CT value in evaluating the efficacy of primary OP zoledronate was higher than that of 25-hydroxyvitamin D. Conclusions Patients with primary OP are at risk of poor efficacy of zoledronate treatment. The changes of vertebral CT value and 25-hydroxyvitamin D level are related to the efficacy of zoledronate in primary OP. OP zoledronate has good efficacy.

备注/Memo

备注/Memo:
基金项目：湖南省自然科学基金项目（2015JJ4037）
更新日期/Last Update: 2022-10-31